MedTrace Logo

Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract

NCT00825721 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2009-01-21

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract

Conditions

  • Nuclear Cataract

Interventions

DRUG

C-KAD Ophthalmic Solution

4 drops applied daily for 360 days

DRUG

C-KAD Ophthalmic Solution

4 drops applied daily for 360 days

DRUG

LiquiTears

4 drops applied daily for 360 days

DRUG

C-KAD Ophthalmic Solution

4 drops applied daily for 360 days

Sponsors & Collaborators

  • Chakshu Research, Inc.

    lead INDUSTRY

Principal Investigators

  • Sanduk Ruit, MD · Tilganga Eye Center

  • Reeta Gurung, MD · Tilganga Eye Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • Nepal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00825721 on ClinicalTrials.gov